Suppression of Myc-induced apoptosis in β cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression

Cell

Volumn 109, Issue 3, 2002, Pages 321-334

  Pelengaris, Stella ^a,b   Khan, Michael ^a   Evan, Gerard I ^b,c  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; PROTEIN BCL X;

ANGIOGENESIS; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INVASION; CANCER REGRESSION; CARCINOGENESIS; CARCINOGENICITY; CELL MATURATION; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; DISEASE MODEL; IN VIVO STUDY; MASKING; MOLECULAR BIOLOGY; MOUSE; NEOPLASM; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALIA;

EID: 0037013147     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(02)00738-9     Document Type: Article

References (51)

1. Constitutive c-myc expression in IL-3-dependent myeloid cell line suppresses cycle arrest and accelerates apoptosis
2. Inducible and reversible beta-cell autoimmunity and hyperplasia in transgenic mice expressing a conditional oncogene
3. E-cadherin as an invasion suppressor
4. Apoptotic cell death induced by c-myc is inhibited by bcl-2
5. Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: Contrasting effects of homozygous and heterozygous p53 loss
6. Beta-cell turnover: Its assessment and implications
7. Angiogenesis is an early event in the generation of myc-induced lymphomas
8. The N-myc oncogene in human neuroblastoma cells: Down-regulation of an angiogenesis inhibitor identified as activin A
9. Essential role for oncogenic Ras in tumour maintenance
10. Molecular dissection of multi-stage tumorigenesis in transgenic mice
11. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene
12. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis
13. Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis
14. Deconstructing myc
15. A matter of life and cell death
16. Proliferation, cell cycle and apoptosis in cancer
17. Induction of apoptosis in fibroblasts by c-myc protein
18. Cooperative interaction between c-myc and bcl-2 proto-oncogenes
19. Reversible tumorigenesis by myc in hematopoietic lineages
20. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes
21. The role of angiogenesis in tumor growth
22. Down-regulation of endothelial cell growth inhibitors by enhanced MYCN oncogene expression in human neuroblastoma cells
23. The hallmarks of cancer
24. C-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines
25. Mitogen-induced expression of the fibroblast growth factor-binding protein is transcriptionally repressed through a non-canonical E-box element
26. Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas
27. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF
28. Activation of the myc oncoprotein leads to increased turnover of thrombospondin-1 mRNA
29. C-Myc-induced sensitization to apoptosis is mediated through cytochrome c release
30. Induction of c-Myc expression suppresses insulin gene transcription by inhibiting NeuroD/BETA2-mediated transcriptional activation
31. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
32. A test gradient system for optimizing density gradient isolation of pancreatic islets
33. Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins
34. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins
35. A mutant p53 antagonizes the deregulated c-myc-mediated enhancement of apoptosis and decrease in leukemogenicity
36. Twist is a potential oncogene that inhibits apoptosis
37. A sensitive and quantitative enzyme-linked immunosorbence assay for the c-myc and N-myc oncoproteins
38. An in vivo function for the transforming Myc protein: Elicitation of the angiogenic phenotype
39. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice
40. Molecular genetics of malignant insulinoma
41. Reversible activation of c-Myc in skin: Induction of a complex neoplastic phenotype by a single oncogenic lesion
42. A causal role for E-cadherin in the transition from adenoma to carcinoma
43. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
44. Involvement of hypoxia-inducible factor 1 in human cancer
45. The Pezcoller lecture: Cancer cell cycles revisited
46. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2
47. Cadherins in cancer: Implications for invasion and metastasis
48. Myc-mediated apoptosis is blocked by ectopic expression of bcl-2
49. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1
50. Overexpression of Bcl-x(L) in beta-cells prevents cell death but impairs mitochondrial signal for insulin secretion
51. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization